Difference between revisions of "Glioblastoma - null regimens"
Jump to navigation
Jump to search
m |
|||
| Line 6: | Line 6: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| + | =Adjuvant therapy, elderly or poor performance status patients= | ||
| + | ==Best supportive care== | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
| + | ===Regimen=== | ||
| + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 20%"|Study | ||
| + | !style="width: 20%"|Dates of enrollment | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 20%"|Comparator | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://doi.org/10.1056/NEJMoa065901 Keime-Guibert et al. 2007] | ||
| + | |2001-2005 | ||
| + | | style="background-color:#1a9851" |Phase 3 (C) | ||
| + | |[[Glioblastoma#Radiation_therapy_2|RT]] x 50 Gy | ||
| + | | style="background-color:#d73027" |Inferior OS | ||
| + | |- | ||
| + | |} | ||
| + | ''No antineoplastic therapy after primary surgery.'' | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
| + | ====Preceding treatment==== | ||
| + | *[[Surgery#CNS_cancer_surgery|Surgery]] | ||
| + | </div></div> | ||
| + | ===References=== | ||
| + | #Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-Speaking Neuro-Oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 Apr 12;356(15):1527-35. [https://doi.org/10.1056/NEJMoa065901 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/17429084/ PubMed] [https://clinicaltrials.gov/study/NCT00430911 NCT00430911] | ||
| + | |||
=Recurrent disease, non-curative therapy= | =Recurrent disease, non-curative therapy= | ||
==Placebo {{#subobject:3fdb9e|Regimen=1}}== | ==Placebo {{#subobject:3fdb9e|Regimen=1}}== | ||
Revision as of 00:20, 17 December 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main GBM page for regimens that include active anticancer treatment.
Adjuvant therapy, elderly or poor performance status patients
Best supportive care
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Keime-Guibert et al. 2007 | 2001-2005 | Phase 3 (C) | RT x 50 Gy | Inferior OS |
No antineoplastic therapy after primary surgery.
Preceding treatment
References
- Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-Speaking Neuro-Oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 Apr 12;356(15):1527-35. link to original article contains dosing details in abstract PubMed NCT00430911
Recurrent disease, non-curative therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Brem et al. 1995 | 1989-1992 | Phase 3 (C) | Gliadel wafer | Inferior OS |
| Westphal et al. 2003 | 1997-1999 | Phase 3 (C) | Gliadel wafer | Seems to have inferior OS |
No active antineoplastic treatment.
References
- Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC; Polymer-Brain Tumor Treatment Group. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995 Apr 22;345(8956):1008-12. link to original article PubMed
- Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003 Apr;5(2):79-88. link to original article link to PMC article PubMed